Table 2. Catalog of previous reports of LTBP1-ALK+ lung cancer.

No.	Year	Chromosomal location	Fusion breakpoint	Response to ALK-TKI	Tumor source	Detection method	VAF	FISH/IHC	References
8	2018	–	–	PR to crizotinib	Tumor	RT-PCR Sanger sequencing	2.7%	+/+	Cristina Aguado, et al.
9	2020	–	(L1-30:A20-29)	PR to crizotinib	Tumor	DNA NGS	13.30%	+/+	Huiwen Qian, et al.

+, positive. LTBP1, latent transforming growth factor beta-binding protein 1; ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; RT-PCR, reverse transcriptase polymerase chain reaction; NGS, next-generation sequencing; VAF, variant frequency; FISH, fluorescent in situ hybridization; IHC, immunochemistry.